Health
ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
Today, AbbVie (NYSE: ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC) ","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"ELAHERE ® was submitted for reimbursement review 180 days prior to Health Canada's approval in line with CDA-AMC's new Target Zero initiative","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":233,"olType":false},{"type":"text","content":"MONTREAL, Oct. 30, 2025 /CNW/ - Today, AbbVie (NYSE: ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1","length":498,"tagName":"p"},{"type":"image","alt":"AbbVie logo (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"AbbVie logo (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":70,"url":"https://media.zenfs.com/en/cnwgroup.com/72740dc64e44042beff5d72ac30381f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ap3tvew83y.AZwoDoMbsXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/72740dc64e44042beff5d72ac30381f7","width":400,"height":70}},"href":"https://mma.prnewswire.com/media/2808459/AbbVie_Canada_ELAHERE__Receives_Positive_Reimbursement_Recommend.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"As part of CDA-AMC's Target Zero initiative—designed to accelerate patient access to promising new treatments by removing delays between Health Canada approval and CDA-AMC's reimbursement recommendation to participating public drug plans2—ELAHERE® was submitted for reimbursement review 180 days prior to Health Canada's approval3, which has resulted in a positive reimbursement recommendation for patients living with certain types of platinum-resistant ovarian cancer, a disease with the lowest survival rate among gynecological cancers in Canada.4 The Target Zero initiative represents a meaningful step towards faster access to innovative new treatmen...